Evidence map›Paper›PMID 26281031›Full record

ReviewBone marrow transplantation2015

Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.

N-C Gorin, S Giebel, M Labopin, B N Savani, M Mohty, A Nagler

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

N-C GorinDepartment of Hematology and Cell Therapy and EBMT, Hôpital Saint-Antoine APHP, INSERM U 938, Université Pierre et Marie Curie UPMC, Paris, France.
S GiebelDepartment of Bone Marrow Transplantation, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
M LabopinDepartment of Hematology and Cell Therapy and EBMT office, Hôpital Saint-Antoine APHP, INSERM U 938, Université Pierre et Marie Curie UPMC, Paris, France.
B N SavaniVanderbilt University Medical Center, Nashville, TN, USA.
M MohtyDepartment of Hematology and Cell Therapy and EBMT office, Hôpital Saint-Antoine APHP, INSERM U 938, Université Pierre et Marie Curie UPMC, Paris, France.
A NaglerHematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Inserm · FRSheba Medical Center · ILThe Maria Sklodowska-Curie National Research Institute of Oncology · PLVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of autologous stem cell transplantation (ASCT) as consolidation therapy for adult patients with acute leukemia has declined over time. However, multiple randomized studies in the past have reported lower relapse rates after autologous transplantation compared with chemotherapy and lower non-relapse mortality rates compared with allogeneic transplantation. In addition, quality of life of long-term survivors is better after autologous transplantation than after allogeneic transplantation. Further, recent developments may improve outcomes of autograft recipients. These include the use of IV busulfan and the busulfan+melphalan combination, better detection of minimal residual disease (MRD) with molecular biology techniques, the introduction of targeted therapies and post-transplant maintenance therapy. Therefore, ASCT may nowadays be reconsidered for consolidation in the following patients if and when they reach a MRD-negative status: good- and at least intermediate-1 risk acute myelocytic leukemia in first CR, acute promyelocytic leukemia in second CR, Ph-positive acute lymphocytic leukemia. Conversely, patients with MRD-positive status or high-risk leukemia should not be considered for consolidation with ASCT.

Indexed as

AdultAutograftsHumansLeukemia, Promyelocytic, AcuteNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaStem Cell Transplantation

Identifiers

PMID26281031
OpenAlexW1158218703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.